“We want to further strengthen Bayer”
Acquisition of Monsanto to create substantial additional value / Record sales and earnings in 2016 / Dividend increase to EUR 2.70 per share proposed / Employees to share in the company's success through total bonuses of over EUR 1.4 billion / Successful start to fiscal 2017 (Source: Bayer Company News)
Source: Bayer Company News - April 28, 2017 Category: Pharmaceuticals Source Type: news
Bayer Receives FDA Approval for Stivarga ® (regorafenib) for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Stivarga is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients previously treated with Nexavar ® (sorafenib) / First new treatment for HCC in a decade / Pivotal Phase III RESORCE trial defines a new treatment plan in HCC which involves use of Stivarga directly after progression on Nexavar (Source: Bayer Company News)
Source: Bayer Company News - April 28, 2017 Category: Pharmaceuticals Source Type: news
Supervisory Board of Bayer AG extends service contract of CFO Johannes Dietsch to the end of May 2018
(Source: Bayer Company News)
Source: Bayer Company News - April 27, 2017 Category: Pharmaceuticals Source Type: news
Strong start to the year for Bayer
Group sales increase by 11.7 percent (Fx& portfolio adj.: 9.4 percent) to EUR 13,244 million / EBITDA before special items raised by 14.9 percent to EUR 3,893 million / Growth momentum across all segments / Very good business development at Pharmaceuticals / Significant increase in sales and earnings at Covestro / Net income 37.9 percent higher at EUR 2,083 million / Core earnings per share advance by 11.5 percent to EUR 2.62 / Group outlook for 2017 raised, driven by Covestro performance (Source: Bayer Company News)
Source: Bayer Company News - April 27, 2017 Category: Pharmaceuticals Source Type: news
Bayer ’s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study (for specialized target groups only)
Study with more than 3,000 patients investigated rivaroxaban 10 mg and 20 mg once daily versus aspirin 100 mg once daily / Both rivaroxaban treatment arms were superior in preventing recurrent venous thromboembolism while showing comparable and very low rates of major bleeding versus aspirin / Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped / Data were presented in a late-breaking clinical trial session at ACC.17 and published simultaneously in The New England Journal of Medicine (Source: Bayer Company News)
Source: Bayer Company News - March 18, 2017 Category: Pharmaceuticals Source Type: news
Bayer places 10.9 percent of Covestro ’s shares with institutional investors
Holding in Covestro reduced to 53.3 percent (Source: Bayer Company News)
Source: Bayer Company News - March 1, 2017 Category: Pharmaceuticals Source Type: news
Bayer to reduce holding in Covestro
Majority stake maintained for the time being (Source: Bayer Company News)
Source: Bayer Company News - February 28, 2017 Category: Pharmaceuticals Source Type: news
Another record year for Bayer – good progress with the acquisition of Monsanto
Group sales increase by 1.5 percent (Fx& portfolio adj. 3.5 percent) to EUR 46,769 million / Substantial sales and earnings increases at Pharmaceuticals / Consumer Health grows with competition / Crop Science successful in a difficult market environment / EBITDA before special items improves by 10.2 percent to EUR 11,302 million / Net income raised by 10.2 percent to EUR 4,531 million / Core earnings per share increase by 7.3 percent to EUR 7.32 / Operating cash flow climbs by 20.8 percent to EUR 8,259 million / Forecast for 2017: further growth in sales and earnings (Source: Bayer Company News)
Source: Bayer Company News - February 22, 2017 Category: Pharmaceuticals Source Type: news
Bayer proposes increased dividend for 2016 of EUR 2.70 per share
Total dividend payout rises 8 percent to EUR 2,233 million (Source: Bayer Company News)
Source: Bayer Company News - February 21, 2017 Category: Pharmaceuticals Source Type: news
Phase III COMPASS study with Bayer ’s Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early (for specialized target groups only)
Coronary or peripheral artery disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke / Rivaroxaban is the only non-vitamin K antagonist oral anticoagulant currently under assessment in this high risk patient population (Source: Bayer Company News)
Source: Bayer Company News - February 8, 2017 Category: Pharmaceuticals Source Type: news
Regorafenib from Bayer Granted Priority Review in the U.S. for Second-Line Treatment of Liver Cancer (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - January 4, 2017 Category: Pharmaceuticals Source Type: news
Aspirin Social Innovation Award for entrepreneurial social pioneers
Innovative concepts for improving health care provision and nutrition / Bayer Board of Management member Malik: “In the future, we’ll be stepping up our support for social innovations that benefit society” (Source: Bayer Company News)
Source: Bayer Company News - December 16, 2016 Category: Pharmaceuticals Source Type: news
